EMA Refused: Folotyn (pralatrexate) — Allos Therapeutics Ltd

View source ↗

Summary

EMA refused approval for Folotyn (pralatrexate) by Allos Therapeutics Ltd for T-cell lymphoma indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Lymphoma

Drugs mentioned

• Folotyn (pralatrexate)

Snippet

Status: Refused. Therapeutic area: Lymphoma, T-Cell. MAH: Allos Therapeutics Ltd. Decision date: 20/01/2012. Orphan medicine